Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis
- 944 Downloads
Genetic polymorphisms of cytochrome P450 enzymes, especially CYP2C19, could influence voriconazole pharmacokinetics. The association between CYP2C19 polymorphisms and voriconazole clinical outcomes is not well established. The aim of this meta-analysis was to evaluate the effect of CYP2C19 polymorphisms on clinical outcomes in patients treated with voriconazole.
PubMed, EMBASE, CENTRAL, ClinicalTrials.gov, and three Chinese databases were searched from their inception to January 2016 to identify eligible trials that reported voriconazole exposure and clinical outcomes of voriconazole according to CYP2C19 polymorphisms. Two reviewers independently reviewed the citations, extracted the data, and assessed the quality of the trials. The meta-analysis was performed using RevMan5.3.
A total of ten studies involving 598 patients were included. Compared with patients with extensive metabolizer (EM) phenotype, patients with poor metabolizer (PM) phenotype had significantly higher trough concentrations (MD, 1.22 mg/L; 95 % confidence interval (CI), 0.72–1.71; P < 0.0001). PM phenotype was also associated with a higher treatment success rate compared with EM phenotype (risk ratio (RR), 1.31; 95 % CI, 1.04–1.67; P = 0.02). However, there was no significant association between CYP2C19 polymorphisms and daily maintenance dose, overall adverse events, hepatotoxicity, and neurotoxicity.
Patients with CYP2C19 PM phenotype were associated with increased treatment success rate and trough concentrations as compared with those with EM phenotype. There was no significant association between CYP2C19 polymorphisms and either daily maintenance dose or adverse outcomes of voriconazole. However, large-scale, high-quality trials are still needed to confirm these findings.
KeywordsCYP2C19 Polymorphism Voriconazole Meta-analysis
The authors would like to thank Drs Dong and Bruggemann for providing the requested data. We also thank Dr Falcione Bonnie who provided language editing.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 7.Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113CrossRefPubMedGoogle Scholar
- 13.Wang LJ, Tang HL, Duan JL (2011) Systematic review of influence on pharmacokinetics of voriconazole on CYP2C19 genetic polymorphisms. Chin J Clin Pharmacol 27:607–611Google Scholar
- 14.Li XF, Yu CY, Cheng Y, Niu TW, Chen K, Tang HL (2016) Effect of cytochrome P450 2C19 genotype on pharmacokinetics of vorivonazole in healthy volunteers: a systematic review and meta-analysis. Chin J Clin Pharmacol 32:267–269Google Scholar
- 20.Tang H, Yan Y, Wang T, Zhang T, Shi W, Fan R, Yao Y, Zhai S (2015) Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. J Assist Reprod Genet 32:1801–1810CrossRefPubMedGoogle Scholar
- 21.Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K (2009) Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 34:91–94CrossRefPubMedGoogle Scholar
- 23.Berge M, Guillemain R, Tregouet DA, Amrein C, Boussaud V, Chevalier P, Lillo-Lelouet A, Le Beller C, Laurent-Puig P, Beaune PH, Billaud EM, Loriot MA (2011) Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 67:253–260CrossRefPubMedGoogle Scholar
- 25.Fu SS, Xiong X, Duan JL, Wang LJ, Liu Y, Jing HM, Zhai SD (2013) Voriconazole plasma concentration monitoring in patients. Chin J Clin Pharmacol 29:622–624Google Scholar
- 26.Kim SH, Lee DG, Kwon JC, Lee HJ, Cho SY, Park C, Kwon EY, Park SH, Choi SM, Choi JH, Yoo JH (2013) Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a Korean population. Infect Chemother 45:406–414CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Liang FH, Meng DM, Xie H, Xiao XL, Lv BJ, Chen WY (2015) CYP2C19 gene polymorphism on plasma concentration of voriconazole in critically ill patients with invasive fungal infections. Chin J Hosp Pharm 35:1456–1461Google Scholar
- 30.Sumonrat C, Jantararoungtong T, Chitasombat MN, Puangpetch A, Prommas S, Dilokpattanamongkol P, Watcharananan SP, Sukasem C (2016) A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Drug Metab Pharmacokinet 31:117–122CrossRefGoogle Scholar
- 31.Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M (2009) Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 89:592–599CrossRefPubMedGoogle Scholar